Dolutegravir Impact on Residual Replication: Dolutegravir Intensification Study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 09 May 2017
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms DIORR
- 07 Jun 2017 Biomarkers information updated
- 03 May 2017 Planned End Date changed from 1 Jun 2017 to 30 Sep 2017.
- 14 Aug 2016 Status changed from recruiting to active, no longer recruiting.